» Articles » PMID: 39037509

Correlates and Predictors of Sarcopenia Among Men with Metastatic Castrate-resistant Prostate Cancer

Overview
Specialty Urology
Date 2024 Jul 22
PMID 39037509
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Sarcopenia is a predictor of clinical outcomes in men with metastatic castrate-resistant prostate cancer (mCRPC); however, correlates and predictors of sarcopenia are poorly understood in this population. The aim of this study was to examine correlates and predictors of sarcopenia in men with mCRPC prior to treatment.

Methods: A secondary analysis of an observational study was performed. Participants were receiving care for mCRPC at the Princess Margaret Cancer Centre. Sarcopenia was assessed prior to treatment and was defined as the combination of low grip strength (<35.5 kg), low gait speed (<0.8 m/s), and computed tomography-derived low muscle mass or density. Participants' sociodemographic and clinical characteristics, comorbidity information, and clinically relevant blood markers were collected prior to treatment and were used to identify correlates and predictors of sarcopenia through Spearman correlations and multivariable logistic regression, respectively.

Results: In total, 110 men had complete data on sarcopenia measures and were included in the analysis. Sarcopenia was identified in 30 (27.3%) participants. Pre-treatment sarcopenia was moderately correlated with dependence in one or more instrumental activities of daily living (IADLs) (r=0.412), Vulnerable Elders Survey-13 (r=0.404), and a lower hemoglobin (r=0.407 per 10 g/L decrease). In adjusted logistic regression, dependence in one or more IADLs (odds ratio [OR] 4.37, 95% confidence interval [CI] 1.37-13.86, p=0.012), and a 10 g/L decrease in hemoglobin (OR 1.70, 95% CI 1.13-2.57, p=0.012) were significantly associated with sarcopenia.

Conclusions: In settings where assessment of sarcopenia is not feasible, evaluation of IADLs and hemoglobin may be used to identify high-risk patients that can benefit from supportive care strategies aiming to improve muscle mass and function.

Citing Articles

Assessment of YouTube Videos Related to Radioactive Iodine Therapy for Thyroid Cancer for Patient Education.

Samson L, Chai B, Ingledew P J Cancer Educ. 2024; .

PMID: 39441521 DOI: 10.1007/s13187-024-02531-9.

References
1.
Cushen S, Power D, Murphy K, McDermott R, Griffin B, Lim M . Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel. Clin Nutr ESPEN. 2017; 13:e39-e45. DOI: 10.1016/j.clnesp.2016.04.001. View

2.
Ikeda T, Ishihara H, Iizuka J, Hashimoto Y, Yoshida K, Kakuta Y . Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer. Jpn J Clin Oncol. 2020; 50(8):933-939. DOI: 10.1093/jjco/hyaa045. View

3.
Frikkel J, Gotte M, Beckmann M, Kasper S, Hense J, Teufel M . Fatigue, barriers to physical activity and predictors for motivation to exercise in advanced Cancer patients. BMC Palliat Care. 2020; 19(1):43. PMC: 7110817. DOI: 10.1186/s12904-020-00542-z. View

4.
Williams G, Chen Y, Kenzik K, McDonald A, Shachar S, Klepin H . Assessment of Sarcopenia Measures, Survival, and Disability in Older Adults Before and After Diagnosis With Cancer. JAMA Netw Open. 2020; 3(5):e204783. PMC: 7218493. DOI: 10.1001/jamanetworkopen.2020.4783. View

5.
Nieder C, Haukland E, Pawinski A, Dalhaug A . Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases. BMC Cancer. 2010; 10:284. PMC: 2894796. DOI: 10.1186/1471-2407-10-284. View